Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lead-212 labeled calcium carbonate microparticles
- Development stage
- Preclinical
- Lead developer
- Oncoinvent
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Beta-minus Emitters → Radiopharmaceuticals, Nanoparticles → Drug Delivery Systems
- Administration
- Intraperitoneal
01
Overview
**Lead-212 labeled calcium carbonate microparticles** is an experimental locoregional **radiopharmaceutical** for internal alpha therapy, consisting of the alpha-emitting radionuclide lead-212 adsorbed onto biocompatible calcium carbonate vaterite microparticles. The particles are designed for administration into body cavities, especially **intraperitoneal** delivery for peritoneal carcinomatosis and ovarian cancer, where decay of lead-212 and its daughters delivers highly localized cytotoxic alpha radiation to nearby tumor deposits without requiring tumor-specific ligand binding. The platform has been associated with development by Oncoinvent as a predecessor and conceptual analogue to radium-224 calcium carbonate microparticles, with similar manufacturing concepts but requiring on-site labeling because of the short approximately 10.6-hour half-life of lead-212.
- Other names
- lead-212 labeled calcium carbonate microparticleslead212 labeled calcium carbonate microparticleslead 212 labeled calcium carbonate microparticleslead-212 calcium carbonate microparticleslead212 calcium carbonate microparticleslead 212 calcium carbonate microparticles212Pb-labeled calcium carbonate microparticles212Pb-CaCO3 microparticleslead-212 labeled vaterite microparticleslead212 labeled vaterite microparticleslead 212 labeled vaterite microparticles
02
Targets
DNA
Beyond the preview
Go deeper on lead-212 labeled calcium carbonate microparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lead-212 labeled calcium carbonate microparticles.